Renapta Overview

  • Founded
  • 2010
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Investors
  • 3

Renapta General Information


Developer of a medical system designed to be used for the treatment of kidney impairment. The company's system is used for developing products for the selective clearance of certain uremic toxins from the blood of end-stage renal disease patients undergoing renal dialysis, enabling patients to access kidney impairment treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Primary Office
  • Van Siburgstraat 34
  • 3863 HW Nijkerk
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Renapta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant Completed Startup
1. Early Stage VC 01-Jan-2010 Completed Startup
To view Renapta’s complete valuation and funding history, request access »

Renapta Executive Team (3)

Name Title Board Seat Contact Info
Francis Houwen Co-Inventor
Jacobus Musters Co-Inventor
You’re viewing 2 of 3 executive team members. Get the full list »

Renapta Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MedSciences Capital Venture Capital Minority 000 0000 000000 0
Relitech Corporation Minority 000 0000 000000 0
Dutch Ministry of Economic affairs Government 000 0000 000000 0
To view Renapta’s complete investors history, request access »